Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 17, 2026 | June 22, 2026 |
| DAVITA INC.DVA · Entity 3482 | Group VP, Government Affairs | September 18, 2020 | September 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,100 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 35,700 · Balance 145,100 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2036-06-17 | Direct | 53,600 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
DAVITA INC.
Report date September 18, 2020 · Filed September 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,590 |
Ending reported balance
After 2020-09-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2020-09-18 · Exercise / conversion · Acquired 26,459 · Balance 51,049 Row 2 · 2020-09-18 · Tax withholding · Disposed 24,190 · Balance 26,859 Row 3 · 2020-09-18 · Exercise / conversion · Acquired 10,464 · Balance 37,323 Row 4 · 2020-09-18 · Tax withholding · Disposed 8,961 · Balance 28,362 Row 5 · 2020-09-18 · Sale · Disposed 2,435 · Balance 25,927 F1: Represents the weighted average sale price of $87.7282. The range of prices for the sale of these shares were $87.4950 - $88.4500 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2020-09-18 · Sale · Disposed 1,337 · Balance 24,590 F2: Represents the weighted average sale price of $88.5658. The range of prices for the sale of these shares was $88.5450 - $88.5900 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $75.42 · Expires 2021-05-13 | Direct | 26,459 |
Reported balance
After 2020-09-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-18 · Exercise / conversion · Disposed 26,459 · Balance 26,459 F3: The Stock Appreciation Rights were granted on 5/13/2016. 50% vested on 5/13/2019 and the remaining 50% vested on 5/13/2020. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $65.48 · Expires 2022-06-06 | Direct | 10,456 |
Reported balance
After 2020-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-18 · Exercise / conversion · Disposed 10,456 · Balance 10,456 F4: The Stock Appreciation Rights were granted on 6/06/2017. 50% vested on 5/15/2020 and the remaining 50% will vest on 5/15/2021. F5: Expiration date previously reported as 5/15/2022 in a Form 4 filed on 6/08/2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sale price of $87.7282. The range of prices for the sale of these shares were $87.4950 - $88.4500 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Represents the weighted average sale price of $88.5658. The range of prices for the sale of these shares was $88.5450 - $88.5900 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: The Stock Appreciation Rights were granted on 5/13/2016. 50% vested on 5/13/2019 and the remaining 50% vested on 5/13/2020.
F4: The Stock Appreciation Rights were granted on 6/06/2017. 50% vested on 5/15/2020 and the remaining 50% will vest on 5/15/2021.
F5: Expiration date previously reported as 5/15/2022 in a Form 4 filed on 6/08/2017.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ADVISORY BOARD CO
Report date November 17, 2017 · Filed November 21, 2017
Section 16 reporting ended · disclosed 2017-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 1
1 source rowRow 1 · 2017-11-17 · Disposition to issuer · Disposed 4,423 · Balance 0 F1: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of the Issuer's common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger was converted into the right to receive $53.81 in cash, without interest (the "Per Share Merger Consideration"), consisting of (i) $52.65 in cash, plus (ii) an additional amount in cash equal to $1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of the Issuer's equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, each share of common stock of Merger Sub outstanding immediately prior to the Merger was converted into one share of Issuer Common Stock, as the surviving corporation in the Merger, and constitutes the only outstanding shares of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2017-11-17 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-11-17 · Disposition to issuer · Disposed 11,409 · Balance 0 F1: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of the Issuer's common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger was converted into the right to receive $53.81 in cash, without interest (the "Per Share Merger Consideration"), consisting of (i) $52.65 in cash, plus (ii) an additional amount in cash equal to $1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of the Issuer's equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, each share of common stock of Merger Sub outstanding immediately prior to the Merger was converted into one share of Issuer Common Stock, as the surviving corporation in the Merger, and constitutes the only outstanding shares of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-17 · Disposition to issuer · Disposed 2,915 · Balance 0 F3: Represents restricted stock units (each, an "RSU") that were outstanding immediately prior to the Merger. By their terms, prior to the Merger, each RSU represented a contingent right to one share of Issuer Common Stock. Each RSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the Per Share Merger Consideration multiplied by the total number of shares of Issuer Common Stock underlying such RSU, payable within two business days following the Merger, provided that to the extent payment within such time or on such date would trigger a tax or penalty under Section 409A of the Internal Revenue Code, such payments shall be made on the earliest date that payment would not trigger such tax or penalty. F1: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F4: The RSUs vest on June 14, 2018. Upon vesting, unless deferred, each RSU is settled by the delivery of the underlying shares of Issuer Common Stock or payment of the current cash value of the vested shares, at the discretion of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer.
F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of the Issuer's common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger was converted into the right to receive $53.81 in cash, without interest (the "Per Share Merger Consideration"), consisting of (i) $52.65 in cash, plus (ii) an additional amount in cash equal to $1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of the Issuer's equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, each share of common stock of Merger Sub outstanding immediately prior to the Merger was converted into one share of Issuer Common Stock, as the surviving corporation in the Merger, and constitutes the only outstanding shares of the Issuer.
F3: Represents restricted stock units (each, an "RSU") that were outstanding immediately prior to the Merger. By their terms, prior to the Merger, each RSU represented a contingent right to one share of Issuer Common Stock. Each RSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the Per Share Merger Consideration multiplied by the total number of shares of Issuer Common Stock underlying such RSU, payable within two business days following the Merger, provided that to the extent payment within such time or on such date would trigger a tax or penalty under Section 409A of the Internal Revenue Code, such payments shall be made on the earliest date that payment would not trigger such tax or penalty.
F4: The RSUs vest on June 14, 2018. Upon vesting, unless deferred, each RSU is settled by the delivery of the underlying shares of Issuer Common Stock or payment of the current cash value of the vested shares, at the discretion of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001204946-26-000001 · primarydocument.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001204946-26-000001 · primarydocument.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,100 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001562180-25-004724 · primarydocument.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2035-06-10 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004724 · primarydocument.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,400 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001562180-24-004904 · primarydocument.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004904 · primarydocument.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,700 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-23-004960 · primarydocument.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004960 · primarydocument.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,700 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-22-004980 · primarydocument.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2032-06-08 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004980 · primarydocument.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 13:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 80,200 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001562180-21-001243 · primarydocument.xml · derivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,200 Underlying: Common Stock · 80,200 shares Expires 2031-02-16 F1 · derivative.exercise_date: The options will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 10,456 | $0.00 Strike: $65.48 | $0.00 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · derivative · entry 8 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,456 Underlying: Common Stock · 10,456 shares Expires 2022-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Appreciation Rights were granted on 6/06/2017. 50% vested on 5/15/2020 and the remaining 50% will vest on 5/15/2021. F5 · derivative.expiration_date: Expiration date previously reported as 5/15/2022 in a Form 4 filed on 6/08/2017. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 26,459 | $0.00 Strike: $75.42 | $0.00 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · derivative · entry 7 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,459 Underlying: Common Stock · 26,459 shares Expires 2021-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Appreciation Rights were granted on 5/13/2016. 50% vested on 5/13/2019 and the remaining 50% vested on 5/13/2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 1,337 | $88.57 | $118,412.47 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 6 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,590 F2 · price: Represents the weighted average sale price of $88.5658. The range of prices for the sale of these shares was $88.5450 - $88.5900 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 2,435 | $87.73 | $213,618.17 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 5 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,927 F1 · price: Represents the weighted average sale price of $87.7282. The range of prices for the sale of these shares were $87.4950 - $88.4500 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 8,961 | $90.14 | $807,744.54 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 4 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,362 Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 10,464 | $65.48 | $685,182.72 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 3 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 24,190 | $90.14 | $2,180,486.60 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,859 Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 26,459 | $75.42 | $1,995,537.78 |
DisclosureSEC source: 0000927066-20-000198 · wf-form4_160081915594568.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:19 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 146 | $79.25 | $11,570.50 |
DisclosureSEC source: 0000927066-20-000107 · wf-form4_158993756038825.xml · nonDerivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,590 F2 · shares: Shares withheld from issuance to satisfy tax withholding obligation in connection with the vesting of 307 shares as described in footnote 1 above. Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:19 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000107 · wf-form4_158993756038825.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,736 F1 · shares: Shares received upon the satisfaction of performance criteria underlying the award of performance stock units granted to the Reporting Person on June 6, 2017. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | GrantStock Appreciation Rights · Derivative | 6,583 | $0.00 Strike: $75.95 | $0.00 |
DisclosureSEC source: 0000927066-20-000054 · wf-form4_158448952252546.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,583 Underlying: Common Stock · 6,583 shares Expires 2025-03-15 F2 · derivative.exercise_date: The stock appreciation rights are scheduled to vest 50% each on March 15, 2023 and March 15, 2024, respectively, subject to the terms and conditions of the applicable award agreement. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 23:59 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 1,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000054 · wf-form4_158448952252546.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Group VP, Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,429 F1 · shares: These restricted stock units are scheduled to vest 50% each on March 15, 2023 and March 15, 2024, subject to continued service through each applicable vesting date. Read SEC document |
| June 20, 2019 Filed Jun 25, 2019 00:35 UTC | DAVITA INC. DVA · Entity 3482 | GrantStock Appreciation Rights · Derivative | 40,000 | $0.00 Strike: $52.41 | $0.00 |
DisclosureSEC source: 0000927066-19-000126 · wf-form4_156142294065336.xml · derivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2024-06-20 F1 · derivative.exercise_date: The stock appreciation rights are scheduled to vest 50% on each of June 20, 2021 and June 20, 2023, respectively, subject to the terms and conditions of the applicable award agreement Read SEC document |
| June 02, 2019 Filed Jun 4, 2019 23:47 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 673 | $43.42 | $29,221.66 |
DisclosureSEC source: 0000927066-19-000105 · wf-form4_155969203267087.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,783 F1 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 1,492 shares, which represent 50% of the restricted stock units granted to the Reporting Person on 6/2/2015. Read SEC document |
| May 15, 2019 Filed May 17, 2019 23:35 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 9,956 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000094 · wf-form4_155813610376939.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,456 F1 · shares: These restricted stock units are scheduled to vest 50% each on 5/15/2022 and 5/15/2023, subject to continued service through each applicable vesting date. F2 · balance_after: Includes 7,508 restricted stock units, which may be settled solely in shares of common stock, that the Reporting Person had previously reported on Table II. F3 · balance_after: The number of shares reported include shares acquired under the DaVita Employee Stock Purchase Plan, exempt under Rule 16b-3. F4 · balance_after: The number of shares reported include shares acquired through the DaVita Retirement Savings Plan. Read SEC document |
| June 02, 2018 Filed Jun 6, 2018 00:18 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 710 | $66.91 | $47,506.10 |
DisclosureSEC source: 0000927066-18-000124 · wf-form4_152824429704371.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,878 F1 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 1,492 shares of common stock underlying the restricted stock units granted to the Reporting Person on 6/2/2015. The remaining 1,492 shares of common stock underlying the restricted stock units granted to the Reporting Person on 6/2/2015 will vest on 6/2/2019, subject to continued service through the vesting date. Read SEC document |
| May 15, 2018 Filed May 18, 2018 01:07 UTC | DAVITA INC. DVA · Entity 3482 | GrantStock Appreciation Rights · Derivative | 37,538 | $0.00 Strike: $66.29 | $0.00 |
DisclosureSEC source: 0000927066-18-000110 · wf-form4_152660559951853.xml · derivative · entry 3 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 Underlying: Common Stock · 37,538 shares Expires 2023-05-15 F2 · security: 50% will vest on each of 5/15/2021 and 5/15/2022, subject to continued service through each applicable vesting date. Read SEC document |
| May 15, 2018 Filed May 18, 2018 01:07 UTC | DAVITA INC. DVA · Entity 3482 | GrantRestricted Stock Units · Derivative | 7,508 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000927066-18-000110 · wf-form4_152660559951853.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,508 Underlying: Common Stock · 7,508 shares Expires 2023-05-15 F2 · security: 50% will vest on each of 5/15/2021 and 5/15/2022, subject to continued service through each applicable vesting date. Read SEC document |
| May 15, 2018 Filed May 18, 2018 01:07 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 848 | $66.83 | $56,671.84 |
DisclosureSEC source: 0000927066-18-000110 · wf-form4_152660559951853.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,588 F1 · shares: Shares withheld from issuance to satisfy tax withholding obligations in connection with the vesting of 1,801 shares of common stock underlying the restricted stock units granted to the Reporting Person on 4/24/2014. The remaining 1,800 shares of common stock underlying the restricted stock units granted to the Reporting Person on 4/24/2014 will vest on 5/15/2019, subject to continued service through the vesting date. Read SEC document |
| March 16, 2018 Filed Mar 21, 2018 01:22 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock · Derivative | 5,200 | $0.00 Strike: $58.94 | $0.00 |
DisclosureSEC source: 0000927066-18-000036 · wf-form4_152159533990535.xml · derivative · entry 3 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires 2018-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: The Stock Appreciation Rights were granted on 3/19/2013. 50% vested on 3/19/2016 and the remaining 50% vested on 3/19/2017. Read SEC document |
| March 16, 2018 Filed Mar 21, 2018 01:22 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 4,414 | $69.45 | $306,552.30 |
DisclosureSEC source: 0000927066-18-000036 · wf-form4_152159533990535.xml · nonDerivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,809 Read SEC document |
| March 16, 2018 Filed Mar 21, 2018 01:22 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 5,200 | $58.94 | $306,488.00 |
DisclosureSEC source: 0000927066-18-000036 · wf-form4_152159533990535.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Apr 14, 2018 00:47 UTC Amendment | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 373 | $69.45 | $25,904.85 |
DisclosureSEC source: 0000927066-18-000059 · wf-form4a_152366685208695.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,436 F1 · shares: The shares withheld to pay taxes were omitted from the reporting person's original Form 4 filed on 3/20/2018. Read SEC document |
| December 08, 2017 Filed Dec 13, 2017 00:57 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 5,400 | $0.00 Strike: $55.34 | $0.00 |
DisclosureSEC source: 0000927066-17-000094 · wf-form4_151312665238950.xml · derivative · entry 4 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,400 shares Expires 2017-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Appreciation Rights were granted on 12/18/2012. 50% vested on 4/1/2015 and the remaining 50% vested on 4/1/2016. Read SEC document |
| December 08, 2017 Filed Dec 13, 2017 00:57 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 949 | $68.19 | $64,711.27 |
DisclosureSEC source: 0000927066-17-000094 · wf-form4_151312665238950.xml · nonDerivative · entry 3 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,023 F1 · price: Represents the weighted average sale price of $68.1889. The range of prices for the sale of these shares was $68.1700 - $68.2100 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2017 Filed Dec 13, 2017 00:57 UTC | DAVITA INC. DVA · Entity 3482 | Tax withholdingCommon Stock | 4,451 | $67.14 | $298,840.14 |
DisclosureSEC source: 0000927066-17-000094 · wf-form4_151312665238950.xml · nonDerivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,972 Read SEC document |
| December 08, 2017 Filed Dec 13, 2017 00:57 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 5,400 | $55.34 | $298,836.00 |
DisclosureSEC source: 0000927066-17-000094 · wf-form4_151312665238950.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 17:05 UTC | ADVISORY BOARD CO ABCO · Entity 171687 | Disposition to issuerRestricted Stock Units · Derivative | 2,915 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-062125 · doc4.xml · derivative · entry 3 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,915 shares Expires not disclosed F3 · derivative.exercise_price: Represents restricted stock units (each, an "RSU") that were outstanding immediately prior to the Merger. By their terms, prior to the Merger, each RSU represented a contingent right to one share of Issuer Common Stock. Each RSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the Per Share Merger Consideration multiplied by the total number of shares of Issuer Common Stock underlying such RSU, payable within two business days following the Merger, provided that to the extent payment within such time or on such date would trigger a tax or penalty under Section 409A of the Internal Revenue Code, such payments shall be made on the earliest date that payment would not trigger such tax or penalty. F1 · date: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F4 · price: The RSUs vest on June 14, 2018. Upon vesting, unless deferred, each RSU is settled by the delivery of the underlying shares of Issuer Common Stock or payment of the current cash value of the vested shares, at the discretion of the Issuer. F4 · derivative.exercise_date: The RSUs vest on June 14, 2018. Upon vesting, unless deferred, each RSU is settled by the delivery of the underlying shares of Issuer Common Stock or payment of the current cash value of the vested shares, at the discretion of the Issuer. F4 · derivative.expiration_date: The RSUs vest on June 14, 2018. Upon vesting, unless deferred, each RSU is settled by the delivery of the underlying shares of Issuer Common Stock or payment of the current cash value of the vested shares, at the discretion of the Issuer. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 17:05 UTC | ADVISORY BOARD CO ABCO · Entity 171687 | Disposition to issuerCommon Stock | 11,409 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-062125 · doc4.xml · nonDerivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · date: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F2 · price: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of the Issuer's common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger was converted into the right to receive $53.81 in cash, without interest (the "Per Share Merger Consideration"), consisting of (i) $52.65 in cash, plus (ii) an additional amount in cash equal to $1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of the Issuer's equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, each share of common stock of Merger Sub outstanding immediately prior to the Merger was converted into one share of Issuer Common Stock, as the surviving corporation in the Merger, and constitutes the only outstanding shares of the Issuer. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 17:05 UTC | ADVISORY BOARD CO ABCO · Entity 171687 | Disposition to issuerCommon Stock | 4,423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-062125 · doc4.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On November 17, 2017, pursuant to that certain Agreement and Plan of Merger, dated as of August 28, 2017 (the "Merger Agreement"), by and among The Advisory Board Company (the "Issuer"), OptumInsight, Inc. ("Optum"), a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth"), and Apollo Merger Sub, Inc., a wholly owned subsidiary of Optum ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Optum (the "Merger"). Immediately preceding the Merger, the Issuer completed the sale of its education business to Avatar Holdco, LLC and EAB Global, Inc. (collectively, "Education Buyer" and formed by Vista Equity Partners Fund VI, L.P.) pursuant to that certain Stock and Asset Purchase Agreement, dated August 28, 2017, by and among the Issuer and the Education Buyer. F2 · price: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of the Issuer's common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger was converted into the right to receive $53.81 in cash, without interest (the "Per Share Merger Consideration"), consisting of (i) $52.65 in cash, plus (ii) an additional amount in cash equal to $1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of the Issuer's equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, each share of common stock of Merger Sub outstanding immediately prior to the Merger was converted into one share of Issuer Common Stock, as the surviving corporation in the Merger, and constitutes the only outstanding shares of the Issuer. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:36 UTC | ADVISORY BOARD CO ABCO · Entity 171687 | GrantRestricted Stock Units · Derivative | 2,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040607 · doc4.xml · derivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,915 Underlying: Common Stock · 2,915 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of ABCO common stock. F2 · derivative.exercise_date: The RSUs vest on June 14, 2018. Upon vesting, each RSU is settled by the delivery of the underlying shares of common stock or payment of the current cash value of the vested shares, at the discretion of the Company. F2 · derivative.expiration_date: The RSUs vest on June 14, 2018. Upon vesting, each RSU is settled by the delivery of the underlying shares of common stock or payment of the current cash value of the vested shares, at the discretion of the Company. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 16:30 UTC | ADVISORY BOARD CO ABCO · Entity 171687 | Exercise / conversionCommon Stock | 4,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038892 · doc4.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 9, 2017 01:05 UTC | DAVITA INC. DVA · Entity 3482 | GrantStock Appreciation Rights · Derivative | 20,929 | $0.00 Strike: $65.48 | $0.00 |
DisclosureSEC source: 0001179110-17-008784 · edgar.xml · derivative · entry 2 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,929 Underlying: Common Stock · 20,929 shares Expires 2022-05-15 F1 · derivative.exercise_date: The Stock Appreciation Rights were granted on 6/6/2017. 50% will vest on 5/15/2020 and the remaining 50% will vest on 5/15/2021. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:24 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 1,800 | $66.32 | $119,377.80 |
DisclosureSEC source: 0001179110-17-007439 · edgar.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,023 F1 · kind: The Restricted Stock Units were granted on 4/24/2014. 50% vested on 5/15/2017 and the remaining 50% will vest on 5/15/2018. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:16 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 807 | $68.72 | $55,460.59 |
DisclosureSEC source: 0001179110-17-003302 · edgar.xml · nonDerivative · entry 1 ZUMWALT LEANNE M · CIK 0001204946 · Grp VP, Purch & Public Affairs 10b5-1 filing: Not disclosed Ownership: Indirect · By Zumwalt 2000 Family Trust Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.